Rivaroxaban in atrial fibrillation

Rivaroxaban in atrial fibrillation

Mariano A Giorgi,1,2 Lucas San Miguel31Cardiology Service, Centro de Educaci&oacute;n M&eacute;dica e Investigaciones Cl&iacute;nicas &ldquo;Norberto Quirno&rdquo;, 2Department of Pharmacology, School of Medicine, Universidad Austral, 3Department of Cardiology...

Full description

Bibliographic Details
Main Authors:	Giorgi MA, Miguel LS
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-08-01
Series:	Vascular Health and Risk Management
Online Access:	http://www.dovepress.com/rivaroxaban-in-atrial-fibrillation-a10865

Similar Items

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019-05-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

Rivaroxaban in non valvular atrial fibrillation: subgroups analysis
by: Cesare Greco
Published: (2015-08-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie AGG
Published: (2014-03-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
by: Chan, Kevin E., et al.
Published: (2016)

Clinical experience of dabigatran and rivaroxaban in electrical cardioversion of atrial fibrillation
by: Charlène Coquard, et al.
Published: (2015-01-01)

Comment on “Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting”
by: Luís Silva Miguel
Published: (2015-11-01)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
by: Jan Beyer-Westendorf, et al.
Published: (2019-04-01)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
by: Robyn Konicki, et al.
Published: (2020-07-01)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
by: Gabriela Lopes Martins, et al.
Published: (2020-07-01)

Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
by: João Morais, et al.
Published: (2014-09-01)

Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
by: João Morais, et al.
Published: (2014-09-01)

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice
by: Vimalesvaran K, et al.
Published: (2018-01-01)

Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban
by: Antovic, J.P, et al.
Published: (2022)

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation
by: I. A. Zolotovskaya, et al.
Published: (2021-05-01)

Prevention of heart embolic complications in atrial fibrillation: Possibilities of using rivaroxaban
by: I S Iavelov
Published: (2013-12-01)

Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
by: Luís Silva Miguel, et al.
Published: (2016-03-01)

Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation
by: Walter Serra, et al.
Published: (2015-09-01)

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
by: Haas S, et al.
Published: (2014-03-01)

Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita
by: S. N. Bel'diev
Published: (2016-03-01)

Simulation of anticoagulation in atrial fibrillation patients with rivaroxaban—from trial to target population
by: Chi Zhang, et al.
Published: (2021-09-01)

A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
by: Jaemin Shim, et al.
Published: (2021-07-01)

Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed
by: Herbert J. A. Rolden, et al.
Published: (2017-10-01)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
by: Jayasree Pillarisetti, et al.
Published: (2020-11-01)

Reply to the comment on “Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting”
by: João Morais
Published: (2015-11-01)

Dabigatran and rivaroxaban in the patients with atrial fibrillation and venous thrombembolism: our first clinical experience
by: Alenka Mavri, et al.
Published: (2015-01-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01)

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for the Prevention of Stroke Prophylaxis in Atrial Fibrillation
by: Harrington, Amanda Rose
Published: (2012)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
by: Hongtao Wei, et al.
Published: (2021-01-01)

A single institution’s experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation
by: Li Xin Chan, et al.
Published: (2018-03-01)

Transesophageal vs. intracardiac echocardiographic screening in patients undergoing atrial fibrillation ablation with uninterrupted rivaroxaban
by: A. Tsyganov, et al.
Published: (2017-06-01)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
by: Faye L. Norby, et al.
Published: (2017-09-01)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
by: Camm AJ, et al.
Published: (2014-07-01)

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
by: Ahrens I, et al.
Published: (2014-02-01)

RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study
by: Roman Piotrowski, et al.
Published: (2019-07-01)

Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report
by: Michele Scarano, et al.
Published: (2017-04-01)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
by: Miller JD, et al.
Published: (2016-05-01)

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke
by: Neda Jaberi, et al.
Published: (2021-01-01)